UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

Date of Report: June 22, 2021

Commission File Number: 001-39307

Legend Biotech Corporation

(Exact Name of Registrant as Specified in its Charter)

2101 Cottontail Lane

Somerset, New Jersey 08873

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒             Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Legend Biotech Announces Advancement of Global Manufacturing Infrastructure and Updates Corporate Presentation

On June 22, 2021, Legend Biotech Corporation (“Legend Biotech”) issued a press release relating to the advancement of its global manufacturing infrastructure.

On June 22, 2021, Legend Biotech also posted an updated version of its corporate presentation, reflecting updates to its product candidate pipeline and manufacturing infrastructure, to its website.

The press release is attached to this Form 6-K as Exhibit 99.1 and the corporate presentation is attached to this Form 6-K as Exhibit 99.2.

EXHIBIT INDEX
Exhibit	Title
99.1	Press Release, dated June 22, 2021.
99.2	Corporate Presentation – June 2021

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	LEGEND BIOTECH CORPORATION
	(Registrant)
June 22, 2021	By:	/s/ Ying Huang
		Ying Huang, Ph.D.
		Chief Executive Officer and Chief Financial Officer